Residency · Residency · Endocrinology

Lipid Disorders and Cardiovascular Risk Management

Lipoprotein Metabolism

Lipoprotein Classes

Understanding lipoprotein metabolism is essential for rational lipid management. Chylomicrons are the largest lipoprotein particles, transporting dietary triglycerides from the intestine to peripheral tissues. They contain apoB-48 and are hydrolyzed by lipoprotein lipase (LPL), with remnants cleared by the liver. Very low-density lipoprotein (VLDL), of hepatic origin, is triglyceride-rich and contains apoB-100. It is progressively hydrolyzed by LPL to produce intermediate-density lipoprotein (IDL) and ultimately low-density lipoprotein (LDL).

LDL is the primary cholesterol-carrying lipoprotein, transporting approximately 70% of circulating cholesterol. It is the principal atherogenic lipoprotein and contains apoB-100, which is cleared from the circulation through hepatic LDL receptors (LDLR). High-density lipoprotein (HDL) is considered anti-atherogenic, mediating reverse cholesterol transport through which cholesterol is removed from peripheral tissues (including macrophage-laden arterial walls) and returned to the liver. HDL contains apoA-I and promotes cholesterol efflux from macrophages via ABCA1 and ABCG1 transporters.

Lipoprotein(a) [Lp(a)] is an LDL-like particle distinguished by the covalent attachment of apolipoprotein(a) to apoB-100. It is independently atherogenic and prothrombotic, genetically determined primarily by the LPA gene, and resistant to statin therapy. Levels exceeding 50 mg/dL (or 125 nmol/L) are associated with significantly increased ASCVD risk.

Key Enzymes and Receptors

The LDL receptor (LDLR) mediates hepatic uptake of LDL particles. It is upregulated by statins through a mechanism involving decreased intracellular cholesterol, which activates SREBP-mediated gene transcription. Mutations in LDLR cause familial hypercholesterolemia. PCSK9 (proprotein convertase subtilisin/kexin type 9) is a serine protease that targets LDLR for lysosomal degradation, effectively reducing the number of LDL receptors on the hepatocyte surface. Gain-of-function mutations in PCSK9 cause severe FH, while loss-of-function mutations, as demonstrated by Cohen and colleagues in the Dallas Heart Study, are associated with lifelong low LDL levels and substantially reduced ASCVD.

Lipoprotein lipase (LPL) hydrolyzes triglycerides in chylomicrons and VLDL; its deficiency causes severe hypertriglyceridemia (type I hyperlipoproteinemia). Cholesteryl ester transfer protein (CETP) transfers cholesterol esters from HDL to VLDL/LDL in exchange for triglycerides. Despite pharmacologic CETP inhibition raising HDL levels, clinical trials with torcetrapib and dalcetrapib failed to demonstrate cardiovascular benefit, and anacetrapib showed only modest benefit without proceeding to development. NPC1L1 (Niemann-Pick C1-Like 1) is the intestinal cholesterol absorption transporter targeted by ezetimibe.

Familial Hypercholesterolemia (FH)

Genetics

Familial hypercholesterolemia is an autosomal codominant disorder and the most common monogenic lipid disorder. Heterozygous FH (HeFH) has a prevalence of 1 in 250, produces LDL levels typically ranging from 190 to 400 mg/dL, and increases ASCVD risk 10-20 fold. Despite its prevalence, it remains frequently undiagnosed. Homozygous FH (HoFH), with a prevalence of 1 in 300,000, produces LDL levels typically exceeding 500 mg/dL, with ASCVD developing in childhood or adolescence. Untreated, survival rarely extends past age 20-30.

The causative genes include LDLR mutations (85-90% of cases, with over 2,000 variants identified), APOB mutations (5-10%, causing defective binding to LDLR), PCSK9 gain-of-function mutations (1-3%), and LDLRAP1 (autosomal recessive, rare).

Diagnosis

The Dutch Lipid Clinic Network Criteria represent the most validated diagnostic scoring system, incorporating LDL level, family history, clinical features, and genetic testing results. A score of 8 or greater indicates definite FH, 6-8 probable FH, and 3-5 possible FH. The Simon Broome Criteria classify FH as definite (genetic mutation confirmed) or possible (LDL above 190 mg/dL with family history). Clinical features include tendon xanthomas (particularly of the Achilles tendon and extensor tendons of the hands, which are pathognomonic), corneal arcus before age 45, xanthelasma, and premature ASCVD (males under 55, females under 65).

Genetic testing is recommended when the clinical diagnosis is uncertain or for cascade screening of family members, using panel testing for LDLR, APOB, and PCSK9. Cascade screening of all first-degree relatives of confirmed FH patients is the most cost-effective strategy for identifying new cases, detecting 1 new FH case per 1.7 relatives tested.

Treatment of FH

Lifestyle modification including a low saturated fat diet and exercise provides modest LDL reduction of approximately 10-15%. High-intensity statin therapy (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) achieves LDL reduction of 50-60% and is the essential first-line agent. Ezetimibe is the first add-on agent, providing an additional 15-25% LDL reduction. PCSK9 inhibitors are employed when LDL remains above target on maximally tolerated statin plus ezetimibe. LDL apheresis, involving extracorporeal removal of apoB-containing lipoproteins every 1-2 weeks, reduces LDL by 50-70% acutely and is used for HoFH or refractory HeFH. Lomitapide, an MTP inhibitor approved exclusively for HoFH at 5-60 mg daily, reduces LDL by 40-50% but carries a risk of hepatic steatosis and requires a REMS program. Evinacumab (Evkeeza), an anti-ANGPTL3 monoclonal antibody FDA-approved for HoFH, reduces LDL by approximately 47% (ELIPSE-HoFH trial) and works independently of LDLR, offering potential for broader application.

<image>A diagram of LDL cholesterol metabolism and pharmacologic targets. Show a hepatocyte cell with key pathways: (1) LDLR on cell surface binding LDL particles (apoB-100) and internalizing them via receptor-mediated endocytosis. (2) PCSK9 pathway: PCSK9 binding to LDLR and directing it to lysosome for degradation (reducing surface LDLR). (3) Inside cell: SREBP pathway activated by low intracellular cholesterol → upregulates LDLR and HMG-CoA reductase genes. (4) HMG-CoA reductase in ER synthesizing cholesterol (mevalonate pathway). Label drug targets: Statins inhibit HMG-CoA reductase; PCSK9 inhibitors (evolocumab, alirocumab) block PCSK9 from binding LDLR; Ezetimibe blocks NPC1L1 in intestinal enterocyte (show separate enterocyte panel); Bempedoic acid inhibits ACL (ATP citrate lyase) upstream of HMG-CoA reductase; Inclisiran (siRNA) silences PCSK9 mRNA in hepatocyte. Show resultant increase in surface LDLR and increased LDL clearance. Use molecular biology illustration style with clear labels.</image>

Lipid-Lowering Therapies

Statins (HMG-CoA Reductase Inhibitors)

Statins remain the cornerstone of ASCVD prevention and the most evidence-based lipid therapy available. High-intensity statins (achieving 50% or greater LDL reduction) include atorvastatin 40-80 mg and rosuvastatin 20-40 mg. Moderate-intensity statins (30-49% LDL reduction) include atorvastatin 10-20 mg, rosuvastatin 5-10 mg, simvastatin 20-40 mg, and pravastatin 40 mg.

The mechanism involves inhibition of HMG-CoA reductase, decreasing hepatic cholesterol synthesis, which triggers upregulation of LDLR expression via SREBP activation and consequently increases LDL clearance from the circulation. Beyond LDL lowering, statins exert pleiotropic effects including anti-inflammatory activity (reducing hsCRP), plaque stabilization, endothelial function improvement, and antioxidant properties.

Landmark trials have established the clinical benefit of statins. The 4S trial (simvastatin, secondary prevention) demonstrated a 30% reduction in total mortality. JUPITER (rosuvastatin, primary prevention in patients with elevated hsCRP) showed a 44% reduction in MACE. The CTT meta-analysis established that every 39 mg/dL (1 mmol/L) reduction in LDL produces a 22% reduction in major vascular events.

Side effects include myalgias (5-10%, usually tolerable, with rhabdomyolysis occurring in less than 0.1%), hepatotoxicity (rare, with transaminase elevation in 1-3%; routine monitoring is no longer recommended), and new-onset diabetes (9-12% increased risk, dose-dependent, primarily in patients already at risk; cardiovascular benefit far outweighs the diabetes risk). True statin intolerance occurs in fewer than 5% of patients and is often attributable to the nocebo effect. Management strategies include trying an alternate statin (hydrophilic agents like rosuvastatin or pravastatin have less muscle penetration), reducing the dose, employing alternate-day dosing, or substituting non-statin alternatives.

Ezetimibe

Ezetimibe blocks the NPC1L1 transporter in the intestinal brush border, reducing cholesterol absorption by 50%. As monotherapy, it achieves LDL reduction of 15-25%, with additive effects when combined with statins. The IMPROVE-IT trial demonstrated that simvastatin plus ezetimibe produced an additional 6.4% relative reduction (2% absolute) in cardiovascular events compared with simvastatin alone in post-ACS patients, establishing ezetimibe as an evidence-based add-on therapy. It is well-tolerated with minimal side effects and no significant drug interactions.

PCSK9 Inhibitors

Evolocumab (Repatha) at 140 mg subcutaneously every 2 weeks or 420 mg monthly and alirocumab (Praluent) at 75-150 mg subcutaneously every 2 weeks or 300 mg monthly are monoclonal antibodies that bind circulating PCSK9, increasing LDLR density on hepatocytes and enhancing LDL clearance. They achieve approximately 50-60% LDL reduction on top of statin therapy.

The FOURIER trial (evolocumab) demonstrated a 15% reduction in MACE over 2 years, with 20% reductions in MI, stroke, and coronary revascularization, achieving LDL levels of approximately 30 mg/dL without mortality benefit within the trial duration. ODYSSEY OUTCOMES (alirocumab) showed a 15% MACE reduction post-ACS, with a post-hoc analysis suggesting all-cause mortality reduction in patients with baseline LDL of 100 mg/dL or greater. Safety data are reassuring: injection site reactions occur in approximately 5%, and no significant adverse signals have been identified with very low LDL levels. The EBBINGHAUS substudy confirmed that neurocognitive function is unaffected. Costs have decreased significantly from initial pricing above $14,000 per year to approximately $5,000-8,000 per year.

Inclisiran (Leqvio)

Inclisiran represents a mechanistic evolution in PCSK9 inhibition. As a small interfering RNA (siRNA), it targets PCSK9 mRNA within hepatocytes, silencing PCSK9 production at the transcriptional level. Dosed at 284 mg subcutaneously at day 0, day 90, then every 6 months (twice yearly), it achieves sustained LDL reduction of approximately 50%. The ORION trials have demonstrated consistent LDL lowering, with the cardiovascular outcome trial (ORION-4) ongoing. FDA approval was granted based on LDL-lowering efficacy. The major advantage is twice-yearly dosing, which may improve adherence compared with biweekly PCSK9 inhibitor injections. It is administered by healthcare providers as an in-office injection.

Bempedoic Acid (Nexletol)

Bempedoic acid inhibits ATP citrate lyase (ACL), an enzyme upstream of HMG-CoA reductase in the cholesterol synthesis pathway. Critically, it is a prodrug activated only in the liver (not in skeletal muscle), explaining the absence of myalgias. It achieves LDL reduction of 15-25% on top of statin therapy and 30-40% in statin-intolerant patients. The CLEAR Outcomes trial demonstrated a 13% reduction in MACE in statin-intolerant patients, establishing it as the first oral non-statin lipid-lowering therapy with proven cardiovascular benefit in this population. It is available as a fixed-dose combination with ezetimibe (Nexlizet: bempedoic acid 180 mg plus ezetimibe 10 mg). Side effects include hyperuricemia with potential gout risk and rare tendon rupture. It may increase statin levels, requiring simvastatin doses of 20 mg or below when co-administered.

Omega-3 Fatty Acids

A critical distinction must be made between omega-3 formulations. Icosapent ethyl (Vascepa), purified EPA at 2 g twice daily (4 g/day total), demonstrated a 25% reduction in MACE in the REDUCE-IT trial among patients with ASCVD or diabetes and elevated triglycerides (135-499 mg/dL) on statin therapy. Its mechanism may extend beyond triglyceride lowering to include anti-inflammatory, membrane stabilization, and anti-thrombotic effects. It is FDA-approved for ASCVD risk reduction. In contrast, mixed EPA/DHA preparations (Lovaza, generic omega-3) at 2-4 g/day reduce triglycerides by 20-30% but showed no cardiovascular benefit in the STRENGTH trial. Only icosapent ethyl (pure EPA) has proven cardiovascular benefit; this distinction is critical in clinical practice.

Fibrates

Fibrates are PPAR-alpha agonists that reduce triglycerides by 30-50% with modest HDL increase. Fenofibrate at 145 mg daily reduces triglycerides but demonstrated no primary cardiovascular benefit in the ACCORD-Lipid or FIELD trials. Their role is primarily limited to severe hypertriglyceridemia (TG exceeding 500 mg/dL) for pancreatitis prevention, with minimal ASCVD benefit. The PROMINENT trial with pemafibrate (a selective PPAR-alpha modulator) showed no reduction in cardiovascular events despite triglyceride lowering, confirming the class effect of fibrate futility for ASCVD prevention.

Bile Acid Sequestrants

Cholestyramine, colesevelam, and colestipol bind bile acids in the intestine, driving increased hepatic bile acid synthesis from cholesterol and consequent LDLR upregulation. They achieve LDL reduction of 15-25% but increase triglycerides (and should be avoided when TG exceeds 300 mg/dL). The Lipid Research Clinics trial demonstrated 19% cardiovascular event reduction with cholestyramine. Their current role is primarily as add-on therapy, with colesevelam offering the additional benefit of glucose lowering (it is also approved for type 2 diabetes).

ASCVD Risk Assessment and Treatment Guidelines

AHA/ACC 2018/2022 Cholesterol Guidelines

Risk Categories and LDL Targets

For very high-risk patients (clinical ASCVD with high-risk features including multiple ASCVD events, recent ACS, diabetes with ASCVD, or FH with ASCVD), the LDL target is below 55 mg/dL per ESC guidelines or below 70 mg/dL per ACC/AHA guidance. For high-risk patients with established ASCVD, high-intensity statin is recommended with ezetimibe added when LDL remains at 70 mg/dL or above, and PCSK9 inhibitors added if LDL persists at 70 mg/dL or above. In primary prevention with LDL at 190 mg/dL or above (likely FH), high-intensity statin is recommended regardless of risk score, with ezetimibe and PCSK9 inhibitors added as needed. For primary prevention in diabetes between ages 40-75, moderate-intensity statin is the minimum, with high-intensity if additional risk factors are present. When the 10-year ASCVD risk reaches 7.5% or greater, moderate-to-high intensity statin is recommended with shared decision-making. At borderline risk (5-7.5%), statin therapy may be considered when risk-enhancing factors are present, including family history, hsCRP of 2 mg/L or greater, Lp(a) of 50 mg/dL or above, CAC score above 0, ABI below 0.9, or metabolic syndrome.

Role of Coronary Artery Calcium (CAC) Score

The CAC score serves as an arbitrator for patients at borderline risk (5-20% 10-year risk). A CAC of 0 indicates very low risk, and statin therapy may be deferred. CAC of 1-99 indicates moderate risk, making statin reasonable. CAC of 100 or greater or at the 75th percentile or above indicates high risk, and statin is recommended. CAC scoring is not recommended for low-risk or already high-risk patients, where it adds little to decision-making.

ESC/EAS 2019 Dyslipidemia Guidelines

The European guidelines adopt more aggressive LDL targets: below 55 mg/dL for very high risk and below 40 mg/dL for patients with recurrent events. They employ a target-based approach (in contrast to the risk-based approach of ACC/AHA) and emphasize achieving both a 50% relative reduction and an absolute LDL target.

<image>A stepped treatment escalation algorithm for LDL-C management. Show a staircase/ladder format with increasing intensity of therapy at each step. Step 1 (base): Lifestyle modification (diet, exercise, weight management). Step 2: Moderate-intensity statin. Step 3: High-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg). Step 4: Add ezetimibe (additional 15-25% LDL reduction). Step 5: Add PCSK9 inhibitor or inclisiran (additional 50-60% LDL reduction). Step 6 (top, for HoFH/refractory): Add lomitapide, evinacumab, or LDL apheresis. On the right side, show approximate LDL levels achievable at each step (starting from 200 mg/dL → 100 → 60 → 45 → 20 mg/dL). Include treatment thresholds: secondary prevention target <70 mg/dL (ACC/AHA) or <55 mg/dL (ESC). For statin intolerance: branch to bempedoic acid + ezetimibe (CLEAR Outcomes pathway). Use clean infographic staircase format with color gradient from green to red indicating increasing CV risk requiring more therapy.</image>

Hypertriglyceridemia

Classification

Triglyceride levels are classified as normal (below 150 mg/dL), borderline (150-199 mg/dL), high (200-499 mg/dL), and very high (500 mg/dL or above).

Severe Hypertriglyceridemia (>500 mg/dL)

Severe hypertriglyceridemia poses a risk of acute pancreatitis that increases above 500 mg/dL and escalates dramatically above 1000 mg/dL. Causes include genetic conditions (familial hypertriglyceridemia, familial chylomicronemia syndrome/LPL deficiency) and secondary factors (uncontrolled diabetes, obesity, alcohol, medications including estrogen, retinoids, protease inhibitors, atypical antipsychotics, beta-blockers, thiazides, and bile acid sequestrants, as well as hypothyroidism, nephrotic syndrome, and pregnancy).

Management follows a stepwise approach: treating the underlying cause (glycemic control, alcohol cessation), implementing a very low-fat diet (below 15% of calories from fat), initiating fibrate therapy (fenofibrate 145 mg), adding omega-3 fatty acids at 2-4 g/day, and, in the setting of acute pancreatitis, maintaining NPO status with IV fluids and considering insulin infusion (which activates LPL and rapidly lowers triglycerides) and heparin infusion (which releases LPL, providing a temporary effect).

Familial chylomicronemia syndrome (FCS), caused by LPL deficiency or mutations in apoC-II, GPIHBP1, or LMF1, produces triglyceride levels often exceeding 1,000-10,000 mg/dL with recurrent pancreatitis, eruptive xanthomas, and lipemia retinalis. Emerging therapies include volanesorsen (anti-apoC-III antisense oligonucleotide) and olezarsen (under investigation).

Lp(a) - Emerging Target

Biology

Lp(a) is an LDL-like particle with apo(a) covalently bound to apoB-100. Its circulating level is 90% genetically determined by the LPA gene and is resistant to modification by diet, exercise, and statin therapy. Lp(a) is both pro-atherogenic (serving as a carrier of oxidized phospholipids) and prothrombotic (possessing structural homology to plasminogen that inhibits fibrinolysis). Elevated Lp(a) above 50 mg/dL (125 nmol/L) is associated with approximately 2-3 times increased ASCVD risk and increased risk of aortic stenosis.

Current and Emerging Therapies

PCSK9 inhibitors provide modest Lp(a) reduction of approximately 25-30% through a mechanism that remains unclear. Several transformative therapies are in development. Pelacarsen, an antisense oligonucleotide targeting LPA mRNA, reduces Lp(a) by approximately 80%, with the Phase 3 HORIZON cardiovascular outcome trial ongoing and the potential to become the first targeted Lp(a) therapy. Olpasiran, an siRNA targeting LPA mRNA, achieves greater than 90% Lp(a) reduction, with the Phase 3 OCEAN(a)-Outcomes trial underway. Lepodisiran, another siRNA approach, produces durable Lp(a) reduction exceeding 90% with extended dosing intervals, with Phase 3 planning in progress.

Current recommendations include measuring Lp(a) at least once in every adult (ESC/EAS recommendation), particularly in patients with premature ASCVD, FH, family history of ASCVD, or recurrent events despite optimal therapy.

Key Clinical Pearls

• The CLEAR Outcomes trial established bempedoic acid as the first oral non-statin lipid-lowering therapy with proven cardiovascular benefit in statin-intolerant patients; it works only in the liver (prodrug), avoiding the myalgias associated with statins
• Only icosapent ethyl (pure EPA, 4 g/day) has proven cardiovascular benefit (REDUCE-IT: 25% MACE reduction); mixed EPA/DHA omega-3 supplements do NOT reduce cardiovascular events (STRENGTH trial); this distinction is critical in clinical practice
• Lp(a) is an independent, genetically determined cardiovascular risk factor that is NOT lowered by statins; measure at least once in every adult; pelacarsen and olpasiran are in Phase 3 trials and may become the first targeted Lp(a)-lowering therapies
• Inclisiran (siRNA against PCSK9) requires only twice-yearly injection, representing a major advancement in adherence compared to biweekly PCSK9 monoclonal antibodies; CV outcome data (ORION-4) are eagerly awaited
• In very high-risk patients (recurrent ASCVD events, FH + ASCVD), LDL <55 mg/dL (or even <40 mg/dL per ESC for recurrent events) is the evidence-based target; achieving this often requires triple therapy (statin + ezetimibe + PCSK9i)
• Severe hypertriglyceridemia (>1000 mg/dL) is a medical emergency due to pancreatitis risk; insulin infusion (even in non-diabetic patients) is the fastest way to lower TG in the acute setting by activating lipoprotein lipase

References

1. Grundy SM, et al. "2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol." Circulation. 2019;139(25):e1082-e1143.
2. Sabatine MS, et al. "Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (FOURIER)." N Engl J Med. 2017;376(18):1713-1722.
3. Bhatt DL, et al. "Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia (REDUCE-IT)." N Engl J Med. 2019;380(1):11-22.
4. Nissen SE, et al. "Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients (CLEAR Outcomes)." N Engl J Med. 2023;388(15):1353-1364.
5. Mach F, et al. "2019 ESC/EAS Guidelines for the Management of Dyslipidaemias." Eur Heart J. 2020;41(1):111-188.

Read this lecture as Markdown